OC
RVMD icon

Oppenheimer & Co’s Revolution Medicines RVMD Stock Holding History

Oppenheimer & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88M Buy
+15,400
New +$2.25M 0.03% 524

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Oppenheimer & Co's RVMD Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in Revolution Medicines (RVMD) in Q2 2026: 15,400 shares worth $2.88M. The stake represents 0.03% of the portfolio and ranks #524 among its holdings.

689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Oppenheimer & Co held 15,400 shares of Revolution Medicines worth $2.88M as of Q2 2026.
  • Revolution Medicines was a new Oppenheimer & Co position in Q2 2026.
  • Revolution Medicines made up 0.03% of Oppenheimer & Co's portfolio in Q2 2026, its #524 holding.
  • 689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.